• ECS to supply its Avani THC10 Softgel Capsules for a UWA clinical trial
• Trial to assess effect of 10mg THC on obstructive sleep apnoea severity and cognitive performance
• ECS continues to support academic research on medicinal cannabis

ECS Botanics Holdings Ltd (ASX: ECS), a leading medicinal cannabis company, is pleased to announce its support for an upcoming investigator-led clinical trial by the Centre for Sleep Science at the University of Western Australia. The trial, registered on the Australian New Zealand Clinical Trials Registry, will assess the therapeutic potential of medicinal cannabis in patients with clinically significant obstructive sleep apnoea (OSA). Under the trial protocol, ECS will provide its Avani THC10 product for use as the investigational treatment. The randomised, double-blind, controlled trial targets the enrolment of 24 participants and is expected to run through 2025. It will examine the impact of 10mg of THC on OSA severity and contributing physiological mechanisms, along with psychomotor and cognitive outcomes. Recruitment is anticipated to commence in July 2025. As a company grounded in science, sustainability and transparency, ECS remains committed to working with researchers, clinicians and regulatory bodies to advance the role of medicinal cannabis in modern healthcare.